Wharton Undergraduate Healthcare Conference addresses impact of COVID-19 on health care – The Daily Pennsylvanian

(Photo from Hannah Gross)

This year's Wharton Undergraduate Healthcare Conference focused on the impact of COVID-19 on the health care industry, featuring speakers from Moderna and NewYork-Presbyterian.

The conference, titled Healthcare in the Wake of COVID-19: The Future of a Changing Industry, took place virtually on Jan. 30. The event included keynote addresses from NewYork-Presbyterian Executive Vice President and Chief Operating Officer Laura Forese and Moderna Chief Medical Officer Tal Zaks, as well as four panels: Health Disparities & Inequities, The Future Of Health Coverage, Outbreaks Of Disease, and Digital Health.

Panelists included legal, medical, and policy experts from a variety of universities and health systems, who shared their experiences with COVID-19. Speakers also addressed the potential long-term impacts of the pandemic on the United States' healthcare system, including an increase in the prevalence of telemedicine, the confrontation of pre-existing health disparities, and the switch to another model of healthcare, such as a single-payer system.

Forese, who oversees operations at 10 hospital campuses in New York, discussed the importance of leadership during the COVID-19 pandemic, focusing on its application to vaccine hesitancy and supply chain coordination. Zaks, a professor of Medicine at the Perelman School of Medicine, discussed the use of mRNA technology in the development of COVID-19 vaccines and other potential uses in healthcare.

During the Outbreaks of Disease panel, panelists discussed the initial response to COVID-19 and attempts to limit its spread.

Abraar Karan, aresident at the Brigham and Women's Hospital and Harvard Medical School, recalled wondering if COVID-19 would be the "next big pandemic" in it's early stages.

"We realized this was going to be really difficult," Karan said. "Its just been a game of trying to stay afloat.

Senior Director of the System-wide Special Pathogens Program at NYC Health + Hospitals Syra Madad said one of the biggest challenges involved adjusting to rapidly changing clinical guidance and resource availability at hospitals.

"Were not used to [the] reuse of PPE, so there was a lot of training that had to go into that, Madad said.

Panelists also discussed how the COVID-19 pandemic impacted all aspects of life, not just health care. Wharton professor Mauro Guilln detailed the pandemic's impact on globalization and business, while Eric Pevzner from the Centers for Disease Control and Prevention's Epidemic Intelligence Service touched on the role of the CDC and the U.S. government in preventing future outbreaks.

Wharton and College junior and WUHC Conference Chair Eric Hsieh said The Future of Health Coverage panel was particularly interesting because of the diversity of fields the panelists came from, including politics, medicine, and law.

Get our newsletter, Dear Penn, delivered to your inbox every weekday morning.

"This led to a back-and-forth discussion about the actual likelihood of a single payer system and about whether employer-sponsored health coverage is sustainable moving forward," Hsieh said.

Despite the virtual format, Conference Committee member and College junior Timothy Lee said WUHC still witnessed high levels of student interaction during the event. Lee said many attendees submitted questions and interacted directly with the keynote speakers, rather than just typing in a Zoom chat.

"It was definitely challenging transitioning to an online Zoom format, while still maintaining the interactive and engaging nature of the WUHC Conference," Lee said. "However, we realized that having this event online opened up a multitude of possibilities in terms of the speakers we could get and who we could market the conference towards.

Here is the original post:
Wharton Undergraduate Healthcare Conference addresses impact of COVID-19 on health care - The Daily Pennsylvanian

‘We’re in a storm’: medical students on the Covid frontline – The Guardian

Abbi Bow, a second-year medical student at the University of Bristol, was just 19 when she began working at one of the citys hospitals on the Covid frontline.

I realise it is a young age to see and work with people on the edge of life, she said. And I do think a lot about the patients I looked after who didnt make it. I remember their names and faces. I dont know if that will ever leave me. Sometimes I see a person in the street who looks like a patient that died and it hits you youre back there with them.

But Bow turns this into a positive. After I become a doctor I will have already been exposed to so much. Learning how to cope with this now will be a benefit in the long term.

When they worked for their A-levels and dreamed of medical school, young people like Bow could not have imagined they would be caught up in a coronavirus crisis.

But more than 500 students from the University of Bristols medical school have donned PPE and worked alongside doctors and nurses in hospitals and GP practices during placements, as volunteers or as healthcare assistants. Many thousands more across the county have done the same.

Bow, now 20, took on a post as a healthcare assistant in April last year and juggles the job with her studies. She works intimately with patients, helping them wash, dress, eat and drink. Some cases stick in her mind.

Quite recently I was helping care for a patient with Covid, said Bow. He was talking but clearly exhausted. His body was tired from fighting Covid. He didnt make it. Its heartbreaking, a very weird experience. Its almost as if the person disappears but the body is still there. His wife is now a widow, his child doesnt have a parent any more.

She helped another patient say goodbye to loved ones via a computer screen because they could not visit. I sat there most of the day holding his hand and playing his favourite music. I was this stranger in full PPE holding his hand but I like to think I brought some comfort.

A third patient Bow worked with was in a coma and looking extremely ill. Then I went in for a shift and she was sat up in bed eating yoghurt. I thought: That cant be the same person. She went over and chatted about the bright pink nail polish the patient was wearing, which her granddaughter had applied before she went into hospital. Its great to think the intervention from us worked and helped her body to fight back. Thats a sweet memory.

Bow remains optimistic. Its sometimes difficult. You wake up and its Groundhog Day. Were not seeing friends and family or going out for dinner or the gym, doing the things we love. Its good to hold on to the idea we will be able to do these things in the future. Once we can, I think well cherish them more.

Luke Ottewell, a 22-year-old fifth year student, has been placed at Gloucestershire Royal hospital helping junior doctors by carrying out tasks such as taking blood samples, inserting cannulas and ordering X-rays.

He was sent home to Spain from university during the first lockdown last spring. But I realised Id rather be here helping out. Ottewell returned in the summer and got stuck in.

Like his fellow fifth years, he has had to balance revision and caring for ill people. His routine as he prepared for his finals was to begin revising at 6.30am, work a 9am-5pm shift at the hospital and then get back to the revision from 5pm-9pm. It has been easier to get out of bed in the morning because of the desire to help out during a national emergency, he said.

Andrew Blythe, the director of the universitys medical programme and a part-time GP, said the students had been exposed to more trauma and stress than most of their predecessors.

Undoubtedly, they are seeing more sicker patients, he said. When they experience death for the first time it is a very powerful and moving experience.

A few have paused their studies because of physical or mental health issues but nobody has dropped out. Their experiences are going to have a profound effect on their whole understanding of medicine. I think for a lot of them the pandemic has motivated them.

Chanelle Smith, another fifth year student aged 22 working with critically ill patients at the Gloucestershire Royal, said her duties ranged from taking bloods to writing discharge summaries. She is about to begin working on the vaccination programme.

Were in a storm, she said. Its hard to remain positive but if we can come through this tunnel well all be so proud. Working in such challenging times makes you stronger. I think its increased my resilience. Its been nerve-racking, humbling, exciting but I feel Im more prepared to be a doctor.

View original post here:
'We're in a storm': medical students on the Covid frontline - The Guardian

The media falsely claims schools are safe: What the science actually says (Part two) – WSWS

This is the second part of a two-part article rebutting a commentary published in the Journal of the American Medical Association (JAMA) Viewpoint, which claims school reopenings are safe. Part One can be read here.

The authors of the JAMA article could have also referenced recent news reports from Austin, Texas, that found positivity rates in schools had climbed over 20 percent. A study conducted by researchers in Michigan and Washington state found that when community infections were low, reopening schools did not seem to make the outbreaks worse. However, when infection rates climbed, schools did contribute to community spread.

A physician and public health professor at George Washington University, Dr. Leana Wen, offered a candid assessment, So, there are two issues: One is that we dont have enough contact tracers all across the country. The second problem is that the community prevalence is just so high that its going to be very difficult to sort out where the infections are originating from.

The CDC has acknowledged that most COVID-19 cases are caused by people who are either presymptomatic or asymptomatic but has deliberately failed to connect these findings to the dangers posed by such transmissions in schools.

Part of the answer to this important question was found in a study funded by the US military and published in the New England Journal of Medicine in December involving Marine recruits during quarantine .

A total of 1,848 recruits volunteered to participate in the study. The average age of these recruits was between 18 and 21, which is just older than high school students, making the results relevant to the question of the pandemics course in schools.

Before entering boot camp, the recruits quarantined for two weeks at home and then two additional weeks on a closed college campus. This involved wearing masks, socially distancing and undergoing daily monitoring of symptoms that included temperature checks.

The volunteers had SARS-Cov-2 PCR testing conducted within two days of their arrival, and again on day 7 and day 14, their last day of supervised quarantine. In the first two days, 16 recruits tested positive, but only one had developed symptoms. By the end of the second week, 35 more participants were found to be infected. Of the 51 volunteers that tested positive, only five had symptoms in the week before their test. That means that less than 10 percent of young adults in this well-controlled study presented with any symptoms.

Additionally, no SARS-CoV-2 infections were identified as a result of daily symptom monitoring. These findings have significant relevance to school openings and highlight that even under the best circumstances, identifying cases among young people will be challenging.

One essential factor that the Democrats, the CDC and the bourgeois press keep silent on is that school closures are a crucial mitigating measure to aid in curtailing community transmission. Teachers and students must have safe environments to conduct classes without fear of becoming infected. But the principal reason for school closures is to suppress the transmission of the virus to protect health systems and avoid further loss of life and spread of disease among the population as a whole.

President Biden and his nominee for education secretary, Miguel Cardona, have gone on record to say that school closures would not help mitigate the pandemic. But it is precisely here that the CDC and proponents of school reopening have avoided referencing the following studies delineating the public health benefit of closing educational institutions:

In a JAMA study published last July 29, the authors had found that statewide school closures in the first wave of the pandemic led to a decline in the incidence of COVID-19 of 62 percent per week. Similarly, mortality saw a 58 percent decrease per week. States that closed earlier saw the most significant relative change per week.

According to a study published in Science , looking at various government interventions used against COVID-19, the combination of the closure of schools and universities, limiting gatherings to 10 people or less, and closing most nonessential businesses reduced the reproductive number, R0, to below one. In other words, it led to an overall reduction in the number of infections in the community. Among the interventions listed, school closures and limiting gatherings to 10 people had the highest impact on mitigating the pandemic.

In a Nature study published in November that ranked the effectiveness of worldwide COVID-19 interventions, the cancellation of small gatherings, closure of educational institutions, border restrictions, increased availability of PPE and individual restrictions were statistically significant in reducing the reproductive number, R0.

A German discussion paper published last July that evaluated the effectiveness of school closures and other pre-lockdown COVID-19 mitigations across three countries, Argentina, Italy and South Korea, found that early interventions that included school closures reduced the total number of COVID-19 deaths and helped flatten the epidemic curve. The authors write, Our preferred estimatesthose that in the main analysis are obtained with the smallest root mean squared prediction errorindicate that the interventions prevented 84%, 29%, and 91% COVID-19 deaths in Argentina, Italy and South Korea, respectively, in comparison to a counterfactual projection. These results are robust across different specifications and show that the effectiveness increases the earlier interventions are enacted. ... The later schools were closed nationwide during the course of the pandemic, the lower the effectiveness of this measure.

The argument being put forth by the Biden administration and the Democrats is a deliberately misleading one. When they assert that school closures do little to halt the pandemic, they mean that without all other aspects of non-pharmaceutical interventions in place, school closures will do little to control community spread of the virus. The study published in Science corroborates that by itself, schools are insufficient to bring the reproductive number under one.

That is not an argument for reopening schools, but for making the closure of schools part of a whole-society effort to control the coronaviruss spread. The fight to prevent school reopenings must be conducted with the struggle to implement a lockdown of nonessential businesses, with full income support for all the workers and small business owners affected.

Donate to the WSWS 2021 New Year Fund

Support the only publication that has told the working class the truth about the coronavirus pandemic and advanced an international socialist perspective in response to the crisis.

The rapid developments of new variants of the coronavirus, such as the B.1.1.7 (also known as the UK variant), circulating widely in the US and many other nations, raises significant new problems for fighting the pandemic. The N501Y mutation in the spike protein of the variants has not only made them more contagious, but it also seems it makes the virus more lethal. There is some evidence that they may also be impacting younger people more severely.

Dr. David Strain, a British physician treating COVID-19 patients and an instructor at the University of Exeters medical school, has seen a rise in admissions to hospitals among younger people and women. He found that the average age of admission to the ICUs has declined from December to January.

After many months of genomic stability in the virus, suddenly, three distinct versions of the SARS-CoV-2 virus on three separate continents have independently acquired similar mutations involving their spike protein. According to a new report published in Wired, that pattern is what scientists refer to as convergent evolution, and its a sign of trouble ahead. This means that separate SARS-CoV-2 viruses have acquired similar mutations that help them evade the human immune response. Examples of convergent evolution in nature include such concurrent and independent phenomena as the evolution of flight by bats, birds and insects.

Dr. Stephen Goldstein, an evolutionary virologist, explained that the variants becoming more infectious is a real benefit to them, from the standpoint of their survivability. They have arrived at the same solution to their dilemma at the same time. If random chance created these mutations, it would improve their odds to acquire the ability to invade as many people as possible. However, it appears that there are selective pressures to these mutations which aid the virus to evade a persons immune system. Vaccines could create these selective pressures as well, but they have been introduced too recently in the course of the pandemic to be the dominant factor presently. (See the link to the study: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants .)

According to Dr. Goldstein, The convergent evolution of wilier versions of the virus might just be a consequence of so many poorly managed government pandemic responses, which didnt marshal sufficient resources or inspire the kind of collective action required to not just crush the initial curve, but keep it crushed.

However, as the virus runs rampant and governments attempt to vaccinate the population quickly in ways that violate protocols without containing the epidemic and looking to force schools open, the consequences could well be additional convergent evolutions that produce an extremely virulent strain of the coronavirus.

This danger was stated most succinctly last week by Dr. Katherine OBrien, director for Immunizations, Vaccines and Biologicals at the World Health Organization:

Risk of variants relative to the vaccines is ever greater when the transmission is very high in the communities. Not only because of variants that have occurred but because of the possibility of additional variants emerging under the pressure of vaccines. We have these amazing tools, and the urgency is to deploy them. But we risk something about those tools if we are also not suppressing transmission to the maximum degree possible where those tools can be effective is setting when there is limited transmission. We have to emphasize about the importance of really crushing transmission now while we are rolling out these new vaccines.

The ruling classes see school openings as necessary to maximize surplus value extraction out of the population. As Bidens top economic aide Brian Deese told a Reuters conference last month, We need to get the schools open so that parents can get back to work. The Biden administration and the Democratic Party, backed by the teachers unions and the Republicans, are playing with fire.

The well-being of the community cannot be left in the hands of any government that places the enrichment of the financial oligarchs over its populations well-being. The concerns being raised by teachers and workers worldwide are validated by the science that must guide humanitys struggle to rid itself of an economic system that not only is a dead weight on social progress, but threatens mass extermination on an unprecedented scale. The pandemic is such a scourge, with the contradictions of capitalism blocking a serious, science-driven response that prioritizes saving lives, not corporate profit.

View original post here:
The media falsely claims schools are safe: What the science actually says (Part two) - WSWS

Florida optometrists push for expanded treatment options, but ophthalmologists arent having it – The Capitolist

A turf war has reignited in Tallahassee between optometrists and ophthalmologists over two newly filed bills in the Florida House and Senate.

The proposals, HB 631 in the House and its Senate companion, SB 876would expand the scope of practice for optometrists to allow them to perform limited surgical procedures and prescribe an expanded list of medications specialties that have long been restricted to ophthalmologists, who have undergone several additional years of specialized training.

Its not a new battle. Similar turf wars between the two groups have flared up in the past, with the pro-optometry side arguing that expanding their scope of practice will introduce competition into the health care market and provide Florida residents with more access to professionalized eye care.

But a statewide association of ophthalmologists says the bill is dangerous and should not be passed.

The idea that an optometrist could become licensed to perform surgery through legislation, instead of completing medical school and residency training, is a dangerous threat to patient safety, saidDr.Sarah Wellik, President of the Florida Society Ophthalmologists. With Florida being the epicenter of the opioid epidemic, it would be catastrophic for the Legislature to expand optometrys prescribing authority to over 4,000 non-medical professionals.

The 2021 battle could soon become more intense as lobbyists line up on both sides to advocate for their respective clients. State Senator Manny Diaz Jr. and State Representative Alex Rizo filed the bills in the Senate and House, respectively. Diaz previously filed legislation to expand the optometrist scope of practice when he served in the Florida House.

While both optometrists and ophthalmologists are both considered eye doctors, optometrists typically undergo four years of instruction after undergraduate school in a professional program that trains them to perform eye exams and vision tests, as well as prescribe glasses and contacts, and monitor eye health for diseases like diabetes, glaucoma and dry eye.

Ophthalmologists, by contrast, have gone to three years of medical school after undergrad, after which they participate in a 1-year internship and a residency of 3 years. Those stints are sometimes followed by a 1 to 2 year fellowship program. Ophthalmologists can perform virtually all of the same procedures as optometrists, but can also perform specialized surgeries and generally can provide a higher level of care for more complex eye problems.

The Florida Optometric Association did not immediately respond to a phone call and email seeking comment for this story.

Related

Link:
Florida optometrists push for expanded treatment options, but ophthalmologists arent having it - The Capitolist

The Association Between Smoking and Subarachnoid Hemorrhage – Neurology Advisor

Genetically determined smoking behavior is associated with an increased risk for non-traumatic subarachnoid hemorrhage (SAH), according to study results published in Stroke.

Data suggest that smoking is an important risk factor for aneurysm formation and rupture. While previous studies have identified an increased risk for non-traumatic SAH among smokers, the causal association is not well understood. The objective of this study was to determine if smoking is causally related to the risk for SAH.

Study researchers conducted this large prospective study with Mendelian Randomization analyses using data from the UK BioBank, a large cohort study with over 500,000 adults (age, 40-69 years) from 2006 to 2010. Of the 408,609 patients evaluated, 132,566 (32%) ever smoked regularly and 902 (0.22%) were diagnosed with SAH.

A polygenic risk score that represents the genetic propensity to smoke was built using individual-level genetic data and included 126 single nucleotide polymorphisms.

There was a strong association between genetic susceptibility to smoking with both smoking initiation and risk of SAH. Each additional SD of the smoking polygenic risk score was associated with a 21 percent increased risk for smoking initiation (odds ratio [OR], 1.21; 95% CI, 1.20-1.21; P <.001) and with a 10 percent increased risk for SAH (OR, 1.10; 95% CI, 1.03-1.17; P =.006).

In the primary Mendelian Randomization analysis using the ratio method, genetic susceptibility to smoking was linked to a 63 percent increase in risk of SAH (OR, 1.63; 95% CI, 1.15-2.31; P =.006). The results were similar on secondary Mendelian Randomization analyses using the inverse variance weighted method (OR, 1.57; 95% CI, 1.13-2.17; P =.007) and the weighted median method (OR, 1.74; 95% CI, 1.06-2.86; P =.03).

Findings indicated that the genetic susceptibility to smoking initiation was associated with a 60 percent increase in the risk of SAH, and, compared with never smokers, this increased risk was similar for those who smoked 0.05 to 20 packs per year (OR, 1.63; 95% CI, 1.01-2.62; P =.04), 20 to 40 packs per year (OR, 1.65; 95% CI, 1.13-2.41; P =.009) and more than 40 packs per year (OR, 1.56; 95% CI, 1.08-2.25; P =.02).

The study had several limitations, according to the study researchers, including potential misclassification of the outcome secondary to use of ICD codes to determine SAH cases, the absence of an independent dataset to confirm the results, and the limited demographic of the study population (all genetically determined White study participants). As a result, findings cannot be applied to other racial and/or ethnic populations.

We found that a stronger genetic predisposition to smoking is significantly associated with an increased risk of SAH. These findings provide important evidence to support a causal relationship between smoking and the risk of SAH, concluded the study researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Acosta JN, Szejko N, Both CP, et al. Genetically determined smoking behavior and risk of nontraumatic subarachnoid hemorrhage. Stroke. Published online January 14, 2021. doi:10.1161/STROKEAHA.120.031622

More here:
The Association Between Smoking and Subarachnoid Hemorrhage - Neurology Advisor

Alzheimers Prediction May Be Found in Writing Tests – The New York Times

Is it possible to predict who will develop Alzheimers disease simply by looking at writing patterns years before there are symptoms?

According to a new study by IBM researchers, the answer is yes.

And, they and others say that Alzheimers is just the beginning. People with a wide variety of neurological illnesses have distinctive language patterns that, investigators suspect, may serve as early warning signs of their diseases.

For the Alzheimers study, the researchers looked at a group of 80 men and women in their 80s half had Alzheimers and the others did not. But, seven and a half years earlier, all had been cognitively normal.

The men and women were participants in the Framingham Heart Study, a long-running federal research effort that requires regular physical and cognitive tests. As part of it, they took a writing test before any of them had developed Alzheimers that asks subjects to describe a drawing of a boy standing on an unsteady stool and reaching for a cookie jar on a high shelf while a woman, her back to him, is oblivious to an overflowing sink.

The researchers examined the subjects word usage with an artificial intelligence program that looked for subtle differences in language. It identified one group of subjects who were more repetitive in their word usage at that earlier time when all of them were cognitively normal. These subjects also made errors, such as spelling words wrongly or inappropriately capitalizing them, and they used telegraphic language, meaning language that has a simple grammatical structure and is missing subjects and words like the, is and are.

The members of that group turned out to be the people who developed Alzheimers disease.

The A.I. program predicted, with 75 percent accuracy, who would get Alzheimers disease, according to results published recently in The Lancet journal EClinicalMedicine.

We had no prior assumption that word usage would show anything, said Ajay Royyuru, vice president of health care and life sciences research at IBM Thomas J. Watson Research Center in Yorktown Heights, N.Y., where the A.I. analysis was done.

Alzheimers researchers were intrigued, saying that when there are ways to slow or stop the illness a goal that so far remains elusive it will be important to have simple tests that can warn, early on, that without intervention a person will develop the progressive brain disease.

What is going on here is very clever said Dr. Jason Karlawish, an Alzheimers researcher at the University of Pennsylvania. Given a large volume of spoken or written speech, can you tease out a signal?

For years, researchers have analyzed speech and voice changes in people who have symptoms of neurological diseases Alzheimers, ALS, Parkinsons, frontotemporal dementia, bipolar disease and schizophrenia, among others.

But, said Dr. Michael Weiner, who researches Alzheimers disease at the University of California, San Francisco, the IBM report breaks new ground.

This is the first report I have seen that took people who are completely normal and predicted with some accuracy who would have problems years later, he said.

The hope is to extend the Alzheimers work to find subtle changes in language use by people with no obvious symptoms but who will go on to develop other neurological diseases.

Each neurological disease produces unique changes in speech, which probably occur long before the time of diagnosis, said Dr. Murray Grossman, a professor of neurology at the University of Pennsylvania and the director of the universitys frontotemporal dementia center.

He has been studying speech in patients with a behavioral form of frontotemporal dementia, a disorder caused by progressive loss of nerves in the brains frontal lobes. These patients exhibit apathy and declines in judgment, self control and empathy that have proved difficult to objectively quantify.

Speech is different, Dr. Grossman said, because changes can be measured.

Early in the course of that disease, there are changes in the pace of the patients speech, with pauses distributed seemingly at random. Word usage changes, too patients use fewer abstract words.

These alterations are directly linked to changes in the frontotemporal parts of the brain, Dr. Grossman said. And they appear to be universal, not unique to English.

Dr. Adam Boxer, director of the neurosciences clinical research unit at the University of California, San Francisco, is also studying frontotemporal dementia. His tool is a smartphone app. His subjects are healthy people who have inherited a genetic predisposition to develop the disease. His method is to show subjects a picture and ask them to record a description of what they see.

We want to measure very early changes, five to 10 years before they have symptoms, he said.

The nice thing about smartphones, Dr. Boxer added, is that you can do all kinds of things. Researchers can ask people to talk for a minute about something that happened that day, he said, or to repeat sounds like tatatatata.

Dr. Boxer said he and others were focusing on speech because they wanted tests that were noninvasive and inexpensive.

Dr. Cheryl Corcoran, a psychiatrist at Icahn School of Medicine at Mount Sinai in New York, hopes to use speech changes to predict which adolescents and young adults at high risk for schizophrenia may go on to develop the disease.

Drugs to treat schizophrenia may help those who are going to develop the disease, but the challenge is to identify who the patients will be. A quarter of people with occasional symptoms saw them go away, and about a third never progressed to schizophrenia although their occasional symptoms persisted.

Guillermo Cecchi, an IBM researcher who was also involved in the recent Alzheimers research, studied speech in 34 of Dr. Corcorans patients, looking for flight of ideas, meaning the instances when patients were off track when talking and spinning off ideas in different directions. He also looked for poverty of speech, meaning the use of simple syntactic structures and short sentences.

In addition, Dr. Cecchi and his colleagues studied another small group consisting of 96 patients in Los Angeles 59 of whom had occasional delusions. The rest were healthy people and those with schizophrenia. He asked these subjects to retell a story that they had just heard, and he looked for the same telltale speech patterns.

In both groups, the artificial intelligence program could predict, with 85 percent accuracy, which subjects developed schizophrenia three years later.

Its been a lot of small studies finding the same signals, Dr. Corcoran said. At this point, she said, we are not at the point yet where we can tell people if they are at risk or not.

Dr. Cecchi is encouraged, although he realizes the studies are still in their infancy.

For us, it is a priority to do the science correctly and at scale, he said. We should have many more samples. There are more than 60 million psychiatric interviews in the U.S. each year but none of those interviews are using the tools we have.

Here is the original post:
Alzheimers Prediction May Be Found in Writing Tests - The New York Times

COVID-19 can hide in the brains of mice, cause neurological issues – Business Insider – Business Insider

Darius Settles was sent home from the emergency room twice after contracting COVID-19 in June. The first time, he was told to come back if his condition worsened. On his second visit, his blood-oxygen levels were normal enough to discharge him again. He died in July, the youngest person killed by the coronavirus in Nashville, Tennessee, at that time.

Situations in which patients seem better, get discharged, then see their conditions worsen, have become common over the course of the pandemic. New research suggests it may be related to infections in the brain.

"People seem to have very nice recovery, lung functions are fine, and we send them home just to find out that three days later, the patient becomes so severe that they died," Mukesh Kumar, a virologist at Georgia State University, told Insider. "That usually can only happen when the brain is involved."

Kumar recently published a study in the journal Viruses that examines how COVID-19 affects the brains of mice.

His results showed that three days after the mice were infected with the coronavirus, they displayed high levels of virus in their lungs. By days five and six, their lungs had started to clear up but their brains showed about 1,000 times more virus than the peak levels found in the lungs. That coincided with the arrival of severe symptoms such as labored breathing, disorientation, and weakness.

The virus also triggered an inflammatory response in the brain, marked by the release of chemical signals called cytokines. Under normal circumstances, cytokines tell the immune system to fight off infection but too many cytokines can instruct the body to attack its own cells, triggering dangerous levels of inflammation. The mice brains in the study showed around 10 to 50 times more cytokines than the lungs.

In some mice, the reaction caused immediate death. But in mice with milder cases, the virus seemed to hide out in the brain indefinitely.

Though results of mice studies don't always hold true for humans, Kumar suspects that the brain is a major target for the coronavirus.

"Our brain doesn't have that good immune response like our lungs or our heart, so whenever the virus goes in the brain, it can replicate very well," Kumar said. "It can stay there for a long time."

Viral replication in the brain could also explain why some coronavirus patients have persistent neurological issues, such as dizziness or brain fog, long after they've tested negative for COVID-19. In some cases, Kumar said, there's a risk these neurological problems may give rise to chronic illnesses such as autoimmune disorders, Parkinson's, or multiple sclerosis.

"Depending upon your immune response or antibody levels, it could cause low levels of inflammation, or maybe make you prone to other disease, or maybe reactivate later," he said. "All these are still outstanding questions because we are still only one year into the pandemic."

A woman improperly wears her face mask in Rome, Italy, on April 29, 2020. Andreas Solaro/AFP/Getty Images

COVID-19 is often described as a respiratory disease, since the coronavirus attacks the lungs first. But some researchers suspect it may be a vascular disease, given that some patients develop blood clots, leaky capillaries, and inflamed blood vessels, which can lead to heart damage or stroke.

ADutch study of 184 coronavirus patients in the ICU found that nearly one-third of patients had blood clots. And aJuly study of 100 COVID-19 patients found that 78 of them had some degree of heart damage. Studies have also suggested that nearly 2% of COVID-19 patients have strokes far more than than the rate of strokes among influenza patients.

But Kumar's study didn't detect any virus in the blood of infected mice.

Instead, his research showed that the virus entered the brain through the nasal passages, before attacking the central nervous system. Part of that nervous system controls our sense of smell, which may explain why many coronavirus patients have trouble smelling. Kumar said it's possible that the virus could reach the brain after entering the mouth as well, but the nose is a more direct pathway.

In mice, the coronavirus seemed to have trouble replicating in organs such as the heart, liver, or kidneys. But an infection in the brain can ultimately damage such organs, Kumar said.

"It doesn't even have to go to every organ, because if it can go to the brain, there are several parts of the brain that control all other organs," he said. "So it could also be possible that you don't even need virus in the lungs to cause lung failure."

A patient who has recovered from COVID-19, gestures next to his son as he leaves the Juarez Hospital in Mexico City, Mexico, July 27, 2020. Edgard Garrido/Reuters

Neurological issues are more common among coronavirus patients than scientists originally thought.

An October study found that 82% of coronavirus patients admitted to a hospital network in Chicago in March and April 2020 had neurological symptoms. The issues ranged from relatively minor headaches, dizziness, and loss of smell to serious conditions like brain damage, strokes, and seizures.

In some cases, these symptoms can linger for at least several months.

A recent study from University of Oxford researchers, which is still awaiting peer review, found that 13% of people who got COVID-19 were diagnosed with a psychiatric or neurological illness within six months of testing positive for the virus. Some patients even showed signs of Parkinson's disease or Guillain-Barr syndrome, a rare autoimmune disorder, but those results weren't statistically significant.

Kumar said it's fairly simple to tell whether a patient has a severe neurological condition, since the issue will likely show up on an MRI or CT scan. But mild neurological problems are often difficult to pinpoint.

"Unfortunately, based on other studies, it could be lifelong," Kumar said. "We know patients who are still showing symptoms who were infected a year ago."

The research he did on mouse brains, however, is difficult to replicate in humans.

"The patient has to die to actually find out if the virus is hiding in the brain," he said.

Originally posted here:
COVID-19 can hide in the brains of mice, cause neurological issues - Business Insider - Business Insider

Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets – Daily Local…

EXTON, Pa., Jan. 29, 2021 /PRNewswire/ --Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering, Launch Dynamix. This innovative, independent service provides monthly benchmarking of newly launched products for the first eighteen months of commercial availability.

This is augmented by a quarterly deep dive into promotional activity, messaging, drivers of use, barriers to uptake, patient types, market access landscape, and degree of disruption surrounding the newly launched product including a mix of both quantitative and qualitative feedback. Clients subscribed to this service received their first monthly pulse on January 15, 2021, including data benchmarking the current launch to relevant historical market entrants at similar post-entry timings.

In rheumatology, Spherix is currently tracking the entry of both Novartis' Cosentyx and Eli Lilly's Taltz in non-radiographic axial spondylarthritis (nr-axSpA), which were approved within weeks of each other in June of last year. Data on the key performance indicators (KPIs), provided in the January publication, are compared to the performance of UCB's Cimzia, which was the first biologic/advanced systemic agent to gain FDA approval for nr-axSpA in March of 2019.

With regard to psoriatic arthritis (PsA), Spherix's new service is available for Janssen's Tremfya, with KPIs benchmarked to Cosentyx, Taltz, Amgen's Otezla, and Pfizer's Xeljanz. Pending FDA approval, Spherix also plans to cover AbbVie's Rinvoq in both ankylosing spondylitis (AS) and PsA, Xeljanz for the treatment of AS, and AstraZeneca's anifrolumab for the treatment of systemic lupus erythematosus.

Inaugural Launch Dynamix coverage in gastroenterology includes tracking and trending of Janssen's Stelara for the treatment of ulcerative colitis (UC), benchmarking the entry of the IL-12/23 inhibitor to the respective Crohn's disease launch, as well as the launch of Xeljanz for the treatment of UC.

In neurology, Spherix is currently covering the launches of Novartis' Kesimpta and BMS' Zeposia, with appropriate benchmarked KPIs to Genentech's Ocrevus, Novartis' Mayzent, EMD Serono's Mavenclad, and Biogen's Vumerity. Pending approval, Spherix will also cover the launch of Janssen's ponesimod, which is expected to be available in the Spring of 2021.

In an area of significant unmet need, the lupus nephritis market is poised for a massive shift with recent drug approvals for GSK's Benlysta (also approved for systemic lupus erythematosus) and Aurinia Pharmaceuticals' Lupkynis. The study will include responses from both nephrologists and rheumatologists, with the first pulse available in February.

Other launches on Spherix's radar with planned 2021 coverage (pending approval) include:

"We are really excited to be able to bring this level of launch detail to our clients," says Lynn Price, Vice President of Strategy and Innovation at Spherix. "The rapid turn-around from fielding to publication and the monthly cadence coupled with quarterly deep-dives provides those with assets in this market or with near-term plans to enter it the perfect tool to keep their finger on the pulse."

About Launch Dynamix

Launch Dynamix is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into patient types initiated, brand perceptions, promotional activity, and drivers and barriers to uptake. The service is offered on a brand-by-brand basis.

Learn more about our services here.

About Spherix Global Insights

Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:

Kristen Henn, Business Development Manager

Email:info@spherixglobalinsights.com

http://www.spherixglobalinsights.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-global-insights-introduces-new-service-focusing-on-recent-launches-in-expanding-immunology-nephrology-and-neurology-markets-301217950.html

SOURCE Spherix Global Insights

Go here to read the rest:
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets - Daily Local...

Interventional Neurology Device Market 2021 Industry Scenario, Strategies, Growth Factors And Forecast 2025 | Medtronic, Johnson and Johnson, Terumo…

Big Market Researchstudy on the 2021Interventional Neurology Device Marketis a powerful resource for industry professionals to analyze the Interventional Neurology Device Market deeply and helps in decision making. The report provides a detailed assessment of market size, revenue structure, CAGR, consumption, profit margin, price, and various influencing factors. Also, the report covers new product development, key trends, market drivers, challenges, restraints, competitive landscape, growing technologies, case studies, new business opportunities, future roadmap, value chain, leading key players profiles, and strategies. Interventional Neurology Device report is a completely valuable source of insightful data for making business decisions and competitive analysis of the Interventional Neurology Device Market.

Ask for a Sample PDF Copy of Interventional Neurology Device Market with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/4163093?utm_source=McC&utm_medium=MWA

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers postCOVID-19crisis. TheInterventional Neurology Device Marketreport aims to provide an additional illustration of the latest scenario, economic slowdown, andCOVID-19impact on the overall industry.

How will this Market Intelligence Report Benefit You?

The Interventional Neurology Device Market is also characterized by a highly complex value chain involving product manufacturers, material suppliers, technology developers, and manufacturing equipment developers. Partnerships between research organizations and the industry players help in streamlining the path from the lab to commercialization. In order to also leverage the first mover benefit, companies need to collaborate with each other so as to develop products and technologies that are unique, innovative and cost effective.

Talk to our Analyst / Ask for a discount on Interventional Neurology Device Market and Get More Information Related to This Report:https://www.bigmarketresearch.com/request-for-discount/4163093?utm_source=McC&utm_medium=MWA

Key questions answered in this report:

Market players have been discussed and profiles of leading players including Top Key Companies:MedtronicJohnson and JohnsonTerumo CorporationPenumbra, Inc.Merit Medical Systems, IncW.L. Gore & AssociatesMicroport Scientific CorporationMedikit Co., Ltd.Stryker

Get Access of Complete Copy of This Report and Avail Instant 10% of Discount by Using Coupon Code [ORG123WA]:https://www.bigmarketresearch.com/checkout/sales/37169

By the product type, the Interventional Neurology Device Market is primarily split into 2020-2025:Embolization & coilingNeurothrombectomy Devices

By the end-users/application, the Interventional Neurology Device Market report covers the following segments 2020-2025:Treatment of Cerebral AneurysmsTreatment of Cerebral VasospasmVertebroplasty

Geographically, this report is segmented into several key Regions along with their respective countries, with production, consumption, revenue (million USD), and market share and growth rate ofInterventional Neurology Device Marketin the following regions:

Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

You May Also Like Our Other Top Trending Reports:

For More Information Regarding Other Similar Trending Report Click on The Given Link:https://www.mccourier.com/ppm-and-it-governance-market-2021-by-investment-feasibility-sales-production-and-company-introduction-hpe-microsoft-oracle/

Contact us:Mr. Abhishek Paliwal5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect:+1-971-202-1575Toll Free:+1-800-910-6452E-mail:help@bigmarketresearch.com

Continue reading here:
Interventional Neurology Device Market 2021 Industry Scenario, Strategies, Growth Factors And Forecast 2025 | Medtronic, Johnson and Johnson, Terumo...

VCA Animal Referral & Emergency Center of Arizona has a neurology department that can treat a variety of conditions – Yahoo News

The Telegraph

Ursula von der Leyen on Monday pinned the blame for the vaccine fiasco that led Brussels to threaten a hard border on the island of Ireland on her trade commissioner Valdis Dombrovskis. The European Commission president threw her deputy, who leads DG Trade, under the bus amid rising anger from EU capitals at her go it alone tactics during last weeks battle with AstraZeneca. Jean-Claude Juncker, Mrs von der Leyen's predecessor, said he was "very much opposed" to her export restriction measures. In a speech in Stuttgart on Sunday, Mr Juncker also said of the EUs vaccine procurement: "It all went too slow, it all should have been done more transparently, even though that would have been difficult." This regulation falls under the responsibility of Mr Dombrovskis, said Eric Marmer, the European Commissions chief spokesman, referring to the former prime minister of Latvia, a Brussels veteran with a reputation for caution. In my country we have a saying, Only the Pope is infallible. Mistakes can happen along the way the important thing is that you recognise them early on, Mr Mamer said. Alexander Stubb, the former prime minister of Finland who campaigned to be appointed European Commission, president was scathing about Mrs Von der Leyen. He said "Number one rule of any leader: if your organisation screws up; never, ever blame your team publicly" Mrs von der Leyen was forced into a humiliating climbdown on Friday after announcing Brussels would trigger Article 16 of the Northern Ireland Protocol, to prevent AstraZeneca vaccines being smuggled into Britain from Northern Ireland. The move, which was announced without notifying Ireland or Britain, would have created a vaccine border after years of Brexit talks to avoid a hard border on the island. After the Irish prime minister called Mrs von der Leyen, the regulation, which could have facilitated a vaccine export ban to non-EU countries including Britain, was amended. Mr Mamer said that the regulation to create an export transparency mechanism, which including the Article 16 measure, was passed provisionally and at speed by the entire College of Commissioners on Friday. Asked by the Telegraph if this was Ms Van der Leyens worst week, he said: We believe that we are on the right track since the beginning of this pandemic in ensuring there is as cohesive and as effective a European response as possible. Mrs von der Leyens attempts to pass the buck cut no ice with EU diplomats, who suggested she had gone rogue, or German MPs in Berlin, who plan to summon Ursula von der Leyen for questioning. In a further blow to Mrs von der Leyen, the move was led by MPs from her own party, Angela Merkel's Christian Democrats (CDU). Mrs von der Leyen has refused calls for a public debate on the debacle in the European Parliament. Instead she will on Tuesday hold closed door meetings with MEPs with parties who approved her appointment. It is understood that Mrs von der Leyen took personal charge of the vaccine row and that DG Trades senior official is Sabine Weyand, whose objections to triggering Article 16 were reported to have been overruled. Ms Weyand is keenly aware of the political sensitivities around the Brexit divorce treatys Northern Ireland Protocol. She was Michel Barniers deputy Brexit negotiator and a key figure in the creation of the Irish border backstop.

More:
VCA Animal Referral & Emergency Center of Arizona has a neurology department that can treat a variety of conditions - Yahoo News

Journal Watch: TXA and Neuro OutcomesMore Than Meets the Eye – EMSWorld

Reviewed This Month

Effect of Out-of-Hospital Tranexamic Acid vs. Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.

Authors: Rowell SE, Meier EN, McKnight B, et al.

Published in: JAMA, 2020 Sep 8; 324(10): 96174. Erratum in: JAMA, 2020 Oct 27; 324(16): 1,683.

Over the last decade, the use of tranexamic acid (TXA) for traumatic hemorrhage control has increased. This was due to the results of a clinical trial, published in 2010, that found early administration of TXA was a cost-effective way to reduce the risk of death in bleeding trauma patients.

Further research has shown that TXA is safe for patients with traumatic brain injury (TBI). In this months Journal Watch, we review a randomized, double-blind multicenter trial designed to examine the efficacy and safety of out-of-hospital administration of tranexamic acid compared to placebo in participants with moderate or severe TBI who were not in shock.

The objective of this trial was to determine whether TXA administered by EMS within two hours of injury improved neurologic outcome. Read that objective carefullyit will be important when putting the results of this trial into context.

Neurologic outcome was measured using the Glasgow Outcome Score-Extended (GOSE). The authors chose to dichotomize this scale into favorable (which included moderate disability or good recovery) and poor (which included severe disability, vegetative state, or death) outcomes.

The authors also examined many secondary outcomes, including 28-day mortality, six-month disability, progression of intracranial hemorrhage, incidence of neurosurgical interventions, hospital-free days, ICU-free days, incidence of seizures, and incidence of thrombotic events, to name a few.

The study was conducted in 12 regions across the U.S. and Canada. It included 39 EMS agencies and 20 trauma centers. To be eligible for enrollment in this trial, patients had to be at least 15 years of age, with moderate or severe blunt or penetrating TBI, a GCS score of 3 to 12, at least one reactive pupil, a systolic blood pressure of at least 90 mm Hg, and an IV in place prior to randomization.

Participants were randomized into one of three treatment groups. The first received a 1-gram IV bolus of TXA by EMS followed by a gram of in-hospital TXA infused over eight hours. The next group received a 2-gram TXA bolus by EMS followed by a placebo infusion. The final group received an IV bolus placebo by EMS and a placebo infusion in the hospital. Study kits that appeared identical were shipped to participating EMS agencies for placement on EMS vehicles in random order. Each vehicle only carried one study kit at a time.

The study was conducted between May 2015 and March 2017 under U.S. regulations for exception from informed consent and the Canadian tricouncil policy statement on ethical conduct in research involving humans.

There were 966 patients included in the analysis. Their average age was 42, and almost three-quarters (74%) were male. The average GCS score was 8. The three study groups were similar when comparing demographics and baseline anatomic and physiologic characteristics as well as injury severity. However, the authors note there were fewer penetrating injuries in the bolus-only group.

The median estimated time from injury to EMS administration of the study drug ranged from 40 to 43 minutes. The median time from EMS administration to the start of the in-hospital infusion ranged from 86 to 96 minutes.

The evaluation of the primary study outcome, favorable or poor neurologic function, revealed no statistically significant difference when comparing TXA to placebo (65% vs. 62%, p=0.16). Therefore, the conclusion of this study was that among patients with moderate or severe TBI, out-of-hospital tranexamic acid administration within two hours of injury did not improve six-month neurologic outcome as measured by the GOSE.

However, as we discuss often in this column, we should not let statistical significance alone guide our judgment of importance. There was a 3% difference in favorable neurologic outcome. While that difference may not be statistically significant, could it be clinically meaningful?

Now, rather than simply read the objective and conclusion of this paper, lets dive a little deeper. As mentioned earlier, the authors also examined several secondary outcomes. When evaluating 28-day mortality, the TXA groups showed a 3% improvement (14% vs. 17%). This result was also not statistically significant, with a p-value of 0.26.

There was also an 8% difference in 28-day mortality when comparing the bolus-only group to the placebo group for those patients with intracranial hemorrhage. This difference was statistically significant (p=0.03). The total number of adverse events was also similar between groups.

Why would the authors report such a cut-and-dried conclusion when there seems to be a trend favoring the use of TXA? Well, the authors indicate in their methods section that the study was specifically designed to evaluate neurologic outcomes at six months. This was specified in the original trial registry on ClinicalTrials.gov. The authors had to stick to the primary outcome that was specified prior to the beginning of trial enrollment for the resulting manuscript.

However, the authors are clear that we should carefully interpret their findings. They state in their discussion that despite no statistically significant difference in the primary outcome in either trial, there were important differences and findings from both trials that warrant consideration and future investigation.

In other words, the results seem to be trending in a favorable direction when EMS administers TXA early. So, rather than to simply conclude from these findings that TXA is not effective in the treatment of TBI, an important next step would be to design studies that specifically evaluate outcomes other than the dichotomous GOSE score at six months.

As with all studies there are limitations here. There were some difficulties in obtaining follow-up data six months after the injury. This is not surprising, given that patients were enrolled prior to giving consent. There was also a low percentage of patients with intracranial hemorrhage enrolled in the study. This may have diluted the treatment differences.

This was a very well done study that will lead to further analysis of TXA administration. It is also a great example of how we should avoid letting a p-value alone guide our judgment of importance.

I hope you have an opportunity to read the manuscript yourself. There are many other interesting results that could not fit into this months Journal Watch. And, as always, I hope to review your study in an upcoming edition soon.

Antonio R. Fernandez, PhD, NRP, FAHA, is a research scientist at ESO and an assistant professor in the department of emergency medicine at the University of North CarolinaChapel Hill. He is on the board of advisors of the Prehospital Care Research Forum at UCLA.

Read this article:
Journal Watch: TXA and Neuro OutcomesMore Than Meets the Eye - EMSWorld

Examining the neurological manifestations of COVID-19 – Contemporary Pediatrics

An investigation looks at the neurological manifestations of COVID-19.

Although coronavirus disease 2019 (COVID-19) is first and foremost a respiratory disease, the past year has shown that the disease can also impact other systems in the body, particularly the cardiovascular system. A report in TheLancet Children & Adolescent Health looks at how the disease shows up in neuroimaging.1

The researchers put out an international call to find cases of children who had encephalopathy that was linked to a severe case of COVID-19. They asked for the clinical history as well as association cerebrospinal fluid and plasma data for each case as well. Each case was looked at by a child neurologist, pediatric infectious disease expert, and central neuroradiology panel. Any case that did not have a direct link to a COVID-19 infection was excluded from the study.

A total of 38 children with neurological disease linked to COVID-19 were found in France, the United Kingdom, the United States, Brazil, Argentina, India, Peru, and Saudi Arabia. The researchers found recurring patterns of disease and the neuroimaging abnormalities seen ranged from mild to severe. The most common neuroimaging patterns found were postinfectious immune-mediated acute disseminated encephalomyelitis-like changes of the brain (16 patients), neural enhancement (13 patients), and myelitis (8 patients). Children with multisystem inflammatory syndrome in children were the ones most likely to have splenial lesions (7 patients) and myositis (4 patients). Complications in the cerebrovascular system were not as common among children and adults. No significant pre-existing conditions were seen in children and most of them had favorable outcomes. Four children who previously been healthy before COVID-19 developed fatal atypical central nervous system co-infections.

The researchers concluded that central nervous system abnormalities have been seen in children who had COVID-19. They urged further research to get a better understanding of how the disease can impact the central nervous system as well as provide information on how to provide long-term follow-up care.

Reference

1. Lindan C, Mankad K, Ram D, et al. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. Lancet Child Adolesc Health. December 15, 2020. Epub ahead of print. doi:10.1016/S2352-4642(20)30362-X

Read more:
Examining the neurological manifestations of COVID-19 - Contemporary Pediatrics

Soterix Medical study to address post-COVID neurological and psychiatric symptoms using at-home neuromodulation and monitoring – PRNewswire

NEW YORK, Jan. 26, 2021 /PRNewswire/ --Soterix Medical Inc. (SMI), the global leader in non-invasive stimulation and synergistic brain imaging technologies, announces a new clinical trial of home-based auricular Vagus Nerve Stimulation (taVNS) for individuals who experience post-COVID neuropsychiatric symptoms, like fatigue, headache, or anxiety. The trial involves an innovative, first-of-its kind home-based neuromodulation solution that combines Soterix Medical's unique wearable taVNS platform, with ElectraRx portal for remote stimulation control, and home-based vital sign monitoring.

Emerging studies show COVID can affect patients during two distinct phases of the disease process: the acute stage, characterized by fever, heart or lung problems, and the post-COVID phase, in which neuropsychiatric symptoms, like fatigue, anxiety and depression, can occur.

Researchers have used the term "neuroCOVID" to describe when the second phase is characterized by one or a combination of neuropsychiatric symptoms like vertigo, loss of smell, headaches, fatigue and irritability as well as anxiety and depression. Some studies estimate one in five COVID patients will develop these long-term symptoms.

The study is supported in part by the National Institutes of Health-funded Delaware Clinical and Translational Research Program to address neuroCOVID symptoms in patients. The trial is designed around a unique technology suite that combines precise vagus nerve stimulation with real-time remote-control as well as remote physiological sensing by the clinical team. The trial is based on the established anti-inflammatory response to vagus nerve stimulation.

Mr. Kamran Nazim, Chief Product Manager of Soterix Medical adds, "This study will leverage our unparalleled expertise in developing noninvasive technologies to stimulate the vagus nerve. Soterix Medical has over a decade of experience designing and deploying the more reliable, targeted, and intelligent non-invasive brain stimulation devices. Our proprietary remote-controlled taVNS system is uniquely optimized for this novel indication."

Ms. Claudia Giselle, Soterix Medical's VP Regulatory Affairs, adds "In addition to Soterix Medical's unique wearable vagus nerve stimulation platform, this trial integrates technology for telemedicine support including video and real-time home-based blood pressure, pulse and oxygen saturation levels. The sophistication of this integrated system is a testament to our commitment to provide the most advanced stimulation and integrated monitoring technologies, for the most important medical indications of our time."

CAUTION: Soterix Medical taVNS platform is limited by Federal (or United States) law to investigational use only.

Media Contact: Mariana Shuster Tel: +1-888-990-8327 Email: [emailprotected]

SOURCE Soterix Medical Inc.

Read this article:
Soterix Medical study to address post-COVID neurological and psychiatric symptoms using at-home neuromodulation and monitoring - PRNewswire

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion…

TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with Metrion Biosciences Limited ("Metrion"), the specialist ion channel CRO and drug discovery company.

Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches.

The collaboration aims to demonstrate the potential of Sosei Heptares' SBDD technologies to address disease-associated ion channels and work towards establishing a leadership position in this area, in a similar way that it has done for G protein-coupled receptors (GPCRs).

As a first step, Sosei Heptares and Metrion will combine their respective capabilities in a drug discovery program to identify novel, highly specific drug leads for further development against a single ion channel associated with neurological diseases.

Metrion will contribute intellectual property, know-how and use of screening models for the nominated ion channel target. Sosei Heptares will apply its technologies for structure determination studies and SBDD. Sosei Heptares will have exclusive, full global rights to all molecules identified and directed to the targets for development by Sosei Heptares. No further financial details are disclosed.

Rob Cooke, Chief Technology Officer of Sosei Heptares, commented: "We are extremely pleased to enter this collaboration with Metrion in the hugely exciting area of ion channels. Their experience enables us to extend our world-leading expertise in Structure-Based Drug Discovery for GPCRs to other membrane proteins where structural input to drug discovery has been more limited. This strategic technology collaboration is the latest in a series we have made with highly innovative companies in recent months designed to strengthen our platform and enhance our discovery and partnering opportunities. In addition to Metrion, these collaborations with Captor Therapeutics in targeted protein degradation and with PharmEnable to access proprietary artificial intelligence-enabled and medicinal chemistry technologies are a key factor to drive our future growth ambitions."

Andrew Southan, Chief Executive Officer of Metrion Biosciences, added: "Resolving the 3D structure of ion channel proteins has great potential to accelerate the discovery of potent, selective new drugs targeting this highly important class of human proteins. This opportunity to combine Metrion Biosciences' depth of target class knowledge and assay expertise with Sosei Heptares' Structure-Based Drug Discovery capabilities has considerable potential to achieve scientific and commercial breakthroughs in this field. On behalf of the entire Metrion team I would like to thank Sosei Heptares for selecting Metrion Biosciences for this work and we look forward to a successful alliance."

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR are trademarks of Sosei Group companies.

For more information, please visit https://www.soseiheptares.com/

LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences' ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

For more information, please visit http://www.metrionbiosciences.com

LinkedIn: @metrion-biosciences | Twitter: @metrion_biosci

Enquiries:

Sosei Heptares Media and Investor RelationsHironoshin Nomura, SVP Investor Relations and Corporate Strategy+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Citigate Dewe Rogerson (for Sosei Heptares)Yas Fukuda Japanese Media+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com

Mark Swallow, David Dible International Media+44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com

Metrion BiosciencesKatie Odgaard Zyme Communications+44 (0)7787 502 947 | katie.odgaard@zymecommunications.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content:http://www.prnewswire.com/news-releases/sosei-heptares-to-explore-structure-based-drug-discovery-sbdd-approaches-to-ion-channels-through-strategic-technology-collaboration-with-metrion-biosciences-301218515.html

SOURCE Sosei Heptares

Company Codes: Berlin:JSS, OTC-PINK:SOLTF, Tokyo:4565, Frankfurt:JSS, Munich:JSS, OtherOTC:SOLTF, Stuttgart:JSS

Read this article:
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion...

Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape – Analysis and…

New York, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p06018975/?utm_source=GNW Application Agricultural, Biomedical (Gene Therapy, Drug Discovery, And Diagnostics), Industrial, and Other Applications [Genetically Modified Foods (GM Foods), Biofuel, And Animal (Livestock) Breeding] End-User - Academic Institutes and Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), and Pharmaceutical and Biopharmaceutical Companies

Regional Segmentation

North America U.S., Canada Europe Germany, France, Italy, U.K., Spain, Switzerland, and Rest-of-Europe Asia-Pacific China, Japan, India, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC) Latin America Brazil, Mexico, and Rest-of-the-Latin America Rest-of-the-World

Growth Drivers

Prevalence of Genetic Disorders and Use of Genome Editing Government and Private Funding Technology Advancement in CRISPR Gene Editing

Market Restraints

CRISPR Gene Editing: Off Target Effects and Delivery Ethical Concerns and Implications with Respect to Human Genome Editing

Market Opportunities

Expanding Gene and Cell Therapy Area CRISPR Gene Editing Scope in Agriculture

Key Companies ProfiledAbcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., Takara Bio

Key Questions Answered in this Report: What is CRISPR gene editing? What is the timeline for the development of CRISPR technology? How did the CRISPR gene editing market evolve, and what is its scope in the future? What are the major market drivers, restraints, and opportunities in the global CRISPR gene editing market? What are the key developmental strategies that are being implemented by the key players to sustain this market? What is the patent landscape of this market? What will be the impact of patent expiry on this market? What is the impact of COVID-19 on this market? What are the guidelines implemented by different government bodies to regulate the approval of CRISPR products/therapies? How is CRISPR gene editing being utilized for the development of therapeutics? How will the investments by public and private companies and government organizations affect the global CRISPR gene editing market? What was the market size of the leading segments and sub-segments of the global CRISPR gene editing market in 2019? How will the industry evolve during the forecast period 2020-2030? What will be the growth rate of the CRISPR gene editing market during the forecast period? How will each of the segments of the global CRISPR gene editing market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2030? Which product segment and application segment are expected to register the highest CAGR for the global CRISPR gene editing market? What are the major benefits of the implementation of CRISPR gene editing in different field of applications including biomedical research, agricultural research, industrial research, gene therapy, drug discovery, and diagnostics? What is the market size of the CRISPR gene editing market in different countries of the world? Which geographical region is expected to contribute to the highest sales of CRISPR gene editing market? What are the reimbursement scenario and regulatory structure for the CRISPR gene editing market in different regions? What are the key strategies incorporated by the players of global CRISPR gene editing market to sustain the competition and retain their supremacy?

Market OverviewThe development of genome engineering with potential applications proved to reflect a remarkable impact on the future of the healthcare and life science industry.The high efficiency of the CRISPR-Cas9 system has been demonstrated in various studies for genome editing, which resulted in significant investments within the field of genome engineering.

However, there are several limitations, which need consideration before clinical applications.Further, many researchers are working on the limitations of CRISPR gene editing technology for better results.

The potential of CRISPR gene editing to alter the human genome and modify the disease conditions is incredible but exists with ethical and social concerns. The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.

The growth is attributed to the increasing demand in the food industry for better products with improved quality and nutrient enrichment and the pharmaceutical industry for targeted treatment for various diseases. Further, the continued significant investments by healthcare companies to meet the industry demand and growing prominence for the gene therapy procedures with less turnaround time are the prominent factors propelling the growth of the global CRISPR gene editing market.

Research organizations, pharmaceutical and biotechnology industries, and institutes are looking for more efficient genome editing technologies to increase the specificity and cost-effectiveness, also to reduce turnaround time and human errors.Further, the evolution of genome editing technologies has enabled wide range of applications in various fields, such as industrial biotech and agricultural research.

These advanced methods are simple, super-efficient, cost-effective, provide multiplexing, and high throughput capabilities. The increase in the geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into significantly higher demand for CRISPR gene editing market.

Furthermore, the companies are investing huge amounts in the research and development of CRISPR gene editing products, and gene therapies. The clinical trial landscape of various genetic and chronic diseases has been on the rise in recent years, and this will fuel the CRISPR gene editing market in the future.

Within the research report, the market is segmented based on product type, application, end-user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CRISPR gene editing. Due to the diverse product portfolio and intense market penetration, Merck KGaA, and Thermo Fisher Scientific Inc. have been the pioneers in this field and have been the major competitors in this market. The other major contributors of the market include companies such as Integrated DNA Technologies (IDT), Genscript Biotech Corporation, Takara Bio Inc, Agilent Technologies, Inc., and New England Biolabs, Inc.

Based on region, North America holds the largest share of CRISPR gene editing market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe Germany Italy France Spain U.K. Switzerland Rest-of-Europe Asia-Pacific Chi
na India Australia South Korea Singapore Japan Rest-of-Asia-Pacific Latin America Brazil Mexico Rest-of-Latin America Rest-of-the-WordRead the full report: https://www.reportlinker.com/p06018975/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Here is the original post:
Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and...

Synthetic Biology Used To Develop a New Type of Genetic Design – Technology Networks

Richard Feynman, one of the most respected physicists of the twentieth century, said "What I cannot create, I do not understand". Not surprisingly, many physicists and mathematicians have observed fundamental biological processes with the aim of precisely identifying the minimum ingredients that could generate them. One such example are the patterns of nature observed by Alan Turing. The brilliant English mathematician demonstrated in 1952 that it was possible to explain how a completely homogeneous tissue could be used to create a complex embryo, and he did so using one of the simplest, most elegant mathematical models ever written. One of the results of such models is that the symmetry shown by a cell or a tissue can "break" under a set of conditions. However, Turing was not able to test his ideas, and it took over 70 years before a breakthrough in biology technique was able to evaluate them decisively. Can Turing's dream be made a reality through Feynman's proposal? Genetic engineering has proved it can.

Now, a research team from the Institute of Evolutionary Biology (IBE), a joint centre of UPF and the Spanish National Research Council (CSIC), has developed a new type of model and its implementation using synthetic biology can reproduce the symmetry breakage observed in embryos with the minimum amount of ingredients possible.

The research team has managed to implement via synthetic biology (by introducing parts of genes of other species into the E. coli bacteria) a mechanism to generate spatial patterns observed in more complex animals, such as Drosophila melanogaster (fruit fly) or humans. In the study, the team observed that the strains of modified E. coli, which normally grow in (symmetrical) circular patterns, do as in the shape of a flower with petals at regular intervals, just as Turing had predicted.

"We wanted to build symmetry breaking that is never seen in colonies of E. coli, but is seen in patterns of animals, and then to discover which are the essential ingredients needed to generate these patterns", says Salva Duran-Nebreda, who conducted this research for his doctorate in the Complex Systems laboratory and is currently a postdoctoral researcher at the IBE Evolution of Technology laboratory.

Bacteria E. coli forming patterns induced by the new synthetic system. Credit: Jordi Pla /ACS.

Using the new synthetic platform, the research team was able to identify the parameters that modulate the emergence of spatial patterns in E. coli . "We have seen that by modulating three ingredients we can induce symmetry breaking. In essence, we have altered cell division, adhesion between cells and long-distance communication capacity (quorum sensing), that is to say, perceive when there is a collective decision", Duran-Nebreda comments.

The observations made in the E. coli model could be applied to more complex animal models or to insect colony design principles. "In the same way that organoids or miniature organs can help us develop therapies without having to resort to animal models, this synthetic system paves the way to understanding as universal a phenomenon as embryonic development in a far simpler in vitro system", says Ricard Sol, ICREA researcher with the Complex Systems group at the IBE, and head of the research.

The model developed in this study, the first of its kind, could be key to understanding some embryonic development events. "We must think of this synthetic system as a platform for learning to design different fundamental biological mechanisms that generate structures, such as the step from a zygote to the formation of a complete organism. Moreover, such knowledge on the frontier between mechanical and biological processes, could be very useful for understanding developmental disorders", Duran-Nebreda concludes.

Reference: Duran-Nebreda S, Pla J, Vidiella B, Piero J, Conde-Pueyo N, Sol R. Synthetic Lateral Inhibition in Periodic Pattern Forming Microbial Colonies. ACS Synth Biol. 2021. doi:10.1021/acssynbio.0c00318.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Visit link:
Synthetic Biology Used To Develop a New Type of Genetic Design - Technology Networks

Experts Predict the Hottest Life Science Tech in 2021 and Beyond – The Scientist

Through the social and economic disruption that COVID-19 caused in 2020, the biomedical research community rose to the challenge and accomplished unprecedented feats of scientific acumen. With a new year ahead of us, even as the pandemic grinds on, we at The Scientist thought it was an opportune time to ask what might be on the life science innovation radar for 2021 and beyond. We tapped three members of the independent judging panel that helped name our Top 10 Innovations of 2020 to share their thoughts (via email) on the year ahead.

Paul Blainey: Value is shifting from the impact of individual technologies (mass spectrometry, cloning, sequencing, PCR, induced pluripotent stem cells, next generation sequencing, genome editing, etc.) to impact across technologies. In 2021, I think researchers will increasingly leverage multiple technologies together in order to generate new insights, as well as become more technology-agnostic as multiple technologies present plausible paths toward research goals.

Kim Kamdar: Partially in reaction to the COVID-19 pandemic, one 2021 headline will be the continued innovation focused on consumerization of healthcare, which is redefining how consumers engage with providers across each stage of care. Consumers are even selective about their healthcare choices now, and the retail powerhouses like CVS and Walmart have and will continue to develop solutions to meet the needs of their customers. While this was already underway prior to the pandemic, the crisis has spurred on this activity with the goal of making healthcare more accessible and affordable and ultimately delivering on better health outcomes for all Americans.

Robert Meagher: I think this is easymRNA delivery. This is something that has been in development for years for numerous applications, but the successful development and FDA emergency use authorization of two COVID-19 vaccines based on this technology shines a very bright spotlight on this technology. The vaccine trials and now widespread use of the vaccines will give developers a lot of data about the technology, and sets a baseline for understanding safety and side effects when considering future therapeutic applications outside of infectious disease.

PB:Single-cell technology is here to stay, although its use will continue to change. One analogy to be drawn is the shift we saw from the popularity ofde novo genome sequencing (during the human genome project and the early part of the NGS [next-generation sequencing] era to the rich array of re-sequencing applications practiced today. I expect new ways to use single-cell technology will continue to be discovered for some time to come.

KK: Innovation in single-cell technology has the potential to transform biological research driving to a level of resolution that provides a more nuanced picture of complex biology. Cost has been a key barrier for broader adoption of single-cell analysis. As better technology is developed, cost will be reduced and there will be an explosion in single-cell research. This dynamic will also allow for broader adoption of single-cell technology from translational research to clinical applications particularly in oncology and immunology.

RM: Yesthere is continuing innovation in this space, and room for continued innovation. One area that we have seen development recently, and I see it continuing, is to study single cells not just in isolation, but coupled with spatial information: understanding single cells and their interactions with their neighbors. I also wonder if the COVID-19 pandemic will spur increased interest in applying single-cell techniques to problems in infectious disease, immunology, and microbiology. A lot of the existing methods for single-cell RNA analysis (for example) work well for human or mammalian cells, but dont work for bacteria or viruses.

PB: The promises of CRISPR and gene editing are extraordinary. I cant wait to see how that field continues to develop.

KK: Much of the CRISPR technology focus since it was unveiled in 2012 has been on its utility to modify genes in human cells with the goal of treating genetic disease. More recently, scientists have shown the potential of using the CRISPR gene-editing technology for treatment of viral disease (essentially a programmable anti-viral that could be used to treat diseases like HIV, HBV, SARS, etc. . . .). These findings, published in Nature Communications, showed that CRISPR can be used to eliminate simian immunodeficiency virus (SIV) in rhesus macaque monkeys. If replicated in humans, in studies that will be initiated this year, CRISPR could be utilized to address HIV/AIDS and potentially make a major impact by moving a chronic disease to one with a functional cure.

PB: New therapeutic modalities that expand the addressable set of diseases are particularly exciting. Cell-based therapies offer versatile platforms for biological engineering that leverage the power of human biology. It is also encouraging to see somatic cell genome editing technology advance toward the clinic for the treatment of serious diseases.

The level of innovation that occurred in 2020 to combat COVID-19 will provide a more rapid, focused, and actionable reaction to future pandemics.

Kim Kamdar, Domain Associates

RM: Besides the great success with mRNA-based vaccines that sets the stage for other clinical technologies based on mRNA delivery, the other area that is really in the spotlight this year is diagnostics. There are a lot of labs and companies, both small and large, that have some really innovative products and ideas for portable and point-of-care diagnostics. For a long time, this was often thought of in terms of a problem for the developing world, or resource-limited locations: think, for example, of diagnostics for neglected tropical diseases. But the COVID-19 pandemic and the associated need for diagnostic testing on a massive scale has caused us to rethink what resource-limited means, and to understand the challenge posed by bottlenecks in supply chains, skilled personnel, and high-complexity laboratory facility. There has been a lot of foundational research over the past couple of decades in rapid, portable, easy-to-use diagnostics, but translating these to clinically useful products often seemed to stall, I suspect for lack of a lucrative market for such tests. But we are now starting to see FDA [emergency use authorization for] home-based tests and other novel diagnostic technologies to address needs with the COVID-19 pandemic, and I suspect that this paves the way for these technologies to start being applied to other diagnostic testing needs.

PB: Seeing the suffering and destruction wrought by COVID-19, it is obvious that we need to be prepared with more extensive, equitable, and better-coordinated response plans going forward. While rapid vaccine development and testing were two bright spots last year, there are so many important areas that demand progress. As we learn about how important details become in a crisisno matter how small or mundanediagnostic technologies and the calibration of public health measures are two areas that merit major focus.

KK: The life science community response to the COVID-19 pandemic has already proven to be light-years ahead of previous responses particularly in areas such as vaccine development and diagnostics. It took more than a year to sequence the genome of the SARS virus in 2002. The COVID-19 genome was sequenced in under a month from the first case being identified. Scientists and clinicians were able to turn that initial information to multiple approved vaccines at a blazing speed. Utilizing messenger RNA (mRNA) as a new therapeutic modality for vaccine development has now been validated. Vaccine science has been forever changed. The pandemic has also focused a much-needed level of attention to diagnostics, forcing a rethink of how to increase access, affordability, and actionability of diagnostic testing. The level of innovation that occurred in 2020 to combat COVID-19 will provide a more rapid, fo
cused, and actionable reaction to future pandemics. In addition, the elevation of a science advisor (Dr. Eric Lander) to a cabinet level position in the Biden administration bodes well for our future ability to ground in data and as President Biden himself framed, refresh and reinvigorate our national science and technology strategy to set us on a strong course for the next 75 years, so that our children and grandchildren may inhabit a healthier, safer, more just, peaceful, and prosperous world.

RM: One thing that really kick-started research to address COVID-19 was the early availability of the complete genome sequence of the SARS-CoV-2 virus, and the ongoing timely deposition of new sequences in nearreal-time as isolates were sequenced. This is in contrast to cases where deposition of large number of sequences may lag an outbreak by months or even years. I foresee the nearreal-time sharing of sequence information to become the new standard. Making the virus itself widely and inexpensively available, in inactivated form, as well as well-characterized synthetic viral RNA standards and proteins also helped spur research.

A trend Im less fond of is the rapid publication of nonpeer reviewed results as preprints online. Theres a great benefit to getting new information out to the community ASAP, but unfortunately I think the rush to get preprints up in some cases results in spreading misleading information. This problem is compounded with uncritical, breathless press releases accompanying the posting of preprints, as opposed to waiting for peer-review acceptance of a manuscript to issue a press release. I think the solution may lie in journals considering innovative approaches to speeding up peer review, or a way to at least perform a basic check for rigor prior to posting a preliminary version of the manuscript. Right now the extremes are: post an unreviewed preprint, or wait months or even years with multiple rounds of peer review including extensive additional experiments to satisfy the curiosity of multiple reviewers for high impact publications. Is there a way to prevent manuscripts from being published as preprints with obvious methodological errors or errors in statistical analysis, while also enabling interesting, well-done yet not fully polished manuscripts to be available to the community?

Paul Blaineyis an associate professor of biological engineering at MIT and a core member of the Broad Institute of MIT and Harvard University. The Blainey lab integrates new microfluidic, optical, molecular, and computational tools for application in biology and medicine. The group emphasizes quantitative single-cell and single-molecule approaches, aiming to enable studies that generate data with the power to reveal the workings of natural and engineered biological systems across a range of scales. Blainey has a financial interest in several companies that develop and/or apply life science technologies: 10X Genomics, GALT, Celsius Therapeutics, Next Generation Diagnostics, Cache DNA, and Concerto Biosciences.

Kim Kamdaris managing partner at Domain Associates, a healthcare-focused venture fund creating and investing in biopharma, device, and diagnostic companies. She began her career as a scientist and pursued drug-discovery research at Novartis/Syngenta for nine years.

Robert Meagheris a principal member of Technical Staff at Sandia National Laboratories. His main research interest is the development of novel techniques and devices for nucleic acid analysis, particularly applied to problems in infectious disease, biodefense, and microbial communities. Most recently this has led to approaches for simplified molecular diagnostics for emerging viral pathogens that are suitable for use at the point of need or in the developing world. Meaghers comments represent his professional opinion but do not necessarily represent the views of the US Department of Energy or the United States government.

More here:
Experts Predict the Hottest Life Science Tech in 2021 and Beyond - The Scientist

Uncertain future: Will Europe’s Green Deal encourage or cripple crop gene-editing innovation? – Genetic Literacy Project

The EU Green Deal and its Farm-to-Fork and Biodiversity Strategies stipulate ambitious policy objectives that will fundamentally impact agricultural businesses and value chains. Are these objectives realistic? And how do they fit with the EUs policies on food security, the internal market, international trade and multilateral economic agreements? As significant conflicts of goals become apparent, the discussion on expectations, preconditions and consequences is now underway.

The Farm to Fork Strategy concretely foresees a reduction of pesticide and fertilizer use of 50% and 20% by 2030, respectively. In addition, 25% of EUs agricultural land is supposed to be put under organic farming conditions, which generally means a reduction in productivity. Unfortunately, the strategy is less concrete about the important role of innovation in general and plant breeding innovation specifically to compensate for productivity losses and to contribute to a more sustainable agriculture.

On July 25, 2018 the European Court of Justice (ECJ) published its ruling on mutagenesis breeding, including targeted genome editing techniques. This ruling subjected new tools like CRISPR Cas-9 to the EUs strict rules and requirements for GMOs, and with that effectively prohibited European plant breeders and farmers from utilizing these powerful technologies. These regulatory obstacles are not based on evidence showing that genome editing poses a risk to human health or the environment, but rather on political interference in the regulatory approval process. The COVID pandemic made this abundantly clear. In July 2020, for example, the EU suspended some of its excessive genetic engineering rules to facilitate the development of COVID vaccines, and has since celebrated the approval of these important drugs while trying to prevent the use of biotechnology in agriculture.

Since the discovery of the laws of genetics by Gregory Mendel in 1866, plant breeders have continuously integrated the latest plant biology innovations into their toolbox to develop enhanced crops that help farmers sustainably grow the food we all depend on.

Europes seed sector, technology developers and public researchers have always been important actors in this evolving effort and remain global leaders in developing improved plant breeding methods. They work tirelessly to provide farmers with crop varieties that fit the needs of a highly productive and sustainable agriculture system and meet the exacting demands of consumers. It is no secret that these experts understand the value of new breeding techniques (NBTs) like CRISPR and want to employ them.

Contrary to the claim of some environmental groups that genome editing provides new avenues of control through modifying specific plant traits, most notably insect and herbicide resistance, industrial applications of this sort are only one aspect of NBT research, and a minor one at that. Our recent survey of 62 private plant breeding companies, 90% of which are small and medium size firms (SMEs), confirms that EU plant breeders are able and willing to use these technologies to develop a wide range of crop species and traits for farmers. From grape vine to wheat, NBTs can generate innovation to protect Europes traditional crops from pests and diseases and other threats posed by climate change.

Independent of their size, many companies are already using NBTs in their R&D pipelines for technology development, gene discovery and to produce improved plant varieties. These activities cover a wide range of agricultural and horticultural cropsfrom the so-called cash crops like maize and soybean to minor crops like pulses, forage crops and chicoryand span a wide diversity of characteristics, including yield, plant architecture, disease and pest resistance, food-quality traits and abiotic stresses like drought and heat.

Link:
Uncertain future: Will Europe's Green Deal encourage or cripple crop gene-editing innovation? - Genetic Literacy Project

Lunar cycles have a secret influence on human reproduction Earth.com – Earth.com

Researchers have found evidence that womens menstrual cycles are synchronized with lunar cycles, including the intensity of moonlight and the moons gravitational pull. The experts theorize that this synchronization was strongest in ancient times and has been widely lost due to modern lifestyles and exposure to artificial light at night.

Study lead author Charlotte Frster holds the Chair of Neurobiology and Genetics at the University of Wrzburg (JMU). We know many animal species in which the reproductive behavior is synchronized with the lunar cycle to increase reproductive success, said Frster.

Both menstrual and lunar cycles have a length of around 29.5 days, which indicates that there is a correlation. The idea is also supported by the results of previous research. For example, multiple older studies show that women who have menstrual cycles that are synced up with the moon have the greatest chances of becoming pregnant.

In addition, two longitudinal studies found a significant connection between lunar cycles and birth rate, with an increase in births during the full moon and a decline in births during the new moon. Further evidence suggests that births are more likely to take place at night when there is a full moon, and in the daytime when there is a new moon.

To investigate, Frster and her team analyzed the timing of the menstrual cycles of 22 women who had kept menstrual diaries for up to 32 years. To our knowledge, this approach to analyzing this type of long-term data has not been used before.

Frster explained that the moon exhibits three distinct cycles that periodically change the intensity of moonlight and its gravitational pull here on Earth.

The researchers determined that all three lunar cycles influence the onset of menstruation in women. They found that moonlight seems to have the strongest effect, while gravitational forces of the moon also contribute.

Not all women follow the cycle of moonlight, and those that do only sync up for certain periods of time. Women under 35 years of age have menstrual cycles that follow the light and dark phases of the moon for an average of 25 percent of the time.

The connection between menstrual and lunar cycles decreases as women age, and also decreases with exposure to artificial light sources at night. For example, women who go to bed late and leave lights on longer do not show signs of synchronization with the moon.

The fact that humans follow the rhythm of gravity could explain why other cycles, such as when we fall asleep or how long we sleep, are temporarily influenced by a full moon or new moon.

According to the researchers, the observations suggest that humans respond not only to rapid changes in gravity, like when we are thrown off balance, but also to slow, recurring gravitational changes.

The study is published in the journal Science Advances.

By Chrissy Sexton, Earth.com Staff Writer

Visit link:
Lunar cycles have a secret influence on human reproduction Earth.com - Earth.com

Message from Director SRH/HRP 28 January 2021 – World Health Organization

Ian Askew, Director, Department of Sexual and Reproductive Health and Research including UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction

Happy new year! I hope that the last few weeks have offered some moments of pause and rest. At HRP we are energized, determined, and very much looking forward to continuing with you the important work of ensuring that every person can achieve the highest possible level of sexual and reproductive health and rights.

The COVID-19 pandemic, and especially the disruption to national health systems it has caused, has expanded the scope of our work at HRP but also refocused global attention on the challenges of gender inequalities, protecting human rights and reducing inequities in access to services. These are challenges which have always characterized HRPs work.

For example, on the International Day to Eliminate Violence Against Women in December, HRP and WHO introduced the RESPECT implementation package with UN Women. This emphasises the continuing need for our work on prevention of violence against women and management of its health consequences at the same time as highlighting new resources on addressing gender-based violence in the context of the pandemic.

Recently we launched Right To A Better World, a documentary series produced by HRP and WHO in partnership with Office of the High Commissioner for Human Rights (OHCHR) and the Oxford Human Rights Hub (OxHRH). This powerful series explores how tactics developed by the human rights movement are crucial for achieving sexual and reproductive health rights. Health is a human right, and Right To A Better World has many powerful stories to tell of how human rights frameworks can strengthen the effectiveness of global efforts towards the fulfilment of the 2030 Agenda for Sustainable Development.

Many of us are experiencing that feeling of life on pause because of the COVID-19 pandemic, but this is especially true for children and adolescents. The pandemic is disrupting their education, interfering with their friendships and relationships, and especially for girls increasing their domestic work and care obligations. For some, it is increasing their vulnerability to abuse and violence. HRP and WHO have worked with UNFPA to develop a technical brief titled NOT ON PAUSE: Responding to the SRH needs of adolescents in the context of the COVID-19 crisis, with practical guidance on what can be done to provide adolescents and young people with comprehensive sexuality education, as well as other SRH interventions.

This is, of course, a long-standing challenge and I was very glad to speak at a recent webinar with other UN and government representatives, as well as several youth representatives, launching the first International Technical and Programmatic Guidance on Out-of-School Comprehensive Sexuality Education. HRP and WHO are especially pleased to have contributed evidence from our research for this important document.

Infertility is a social and public health problem that is all too often neglected and stigmatised. More affordable, accessible and acceptable services are needed urgently to address infertility worldwide, as this new research from HRP and WHO shows. I am very glad to say that the infertility Guideline Development Group met online late last year, taking major steps towards developing this long overdue global guidance which should help countries to develop and improve services and care for the millions of people living with infertility and its consequences.

On Universal Health Coverage Day in December, we celebrated the launch of the WHO UHC Compendium of Health Interventions and highlighted the importance of integrating sexual and reproductive health services into national UHC planning. Colleagues in Burkina Faso and Thailand shared how they are achieving this, and in some cases even raising the level of service provision during the pandemic very inspiring.

December was also an exciting month for our collaborative work in striving to mobilise a new era of maternal and perinatal health, in which womens values and preferences are at the centre of their own care.

At the December FIGO Africa Regional Kigali Congress we introduced the Antenatal Care Portal, a one-stop shop' for evidence and tools to support country adaptation and implementation of WHO ANC recommendations. This will be a be a key link between policy-makers, health workers and women and will be regularly updated, reflecting our living guideline approach to maternal health.

We also launched the new Labour Care Guide and accompanying Users Manual, tools for putting the WHO recommendations on intrapartum care into practice. The Labour Care Guide revises and replaces the traditional WHO partograph, an important step forward in evidence-based, individualized labour care.

Our community is saddened by the recent death of Dr Alexander Kessler, HRPs co-founder and first director in 1972. Alexs dynamic and determined leadership, and his truly global commitment to improving the lives of people around the world, live on through HRPs commitment to rigorous research, international cooperation and sexual and reproductive health and rights for all.

2021 begins with some much-needed positive news, as the United States commits to remaining a Member State of WHO. In particular, we celebrate the announcement of support for womens and girls sexual and reproductive health and reproductive rights in the United States as well as globally, and the revocation of the Mexico City Policy.

Still, before turning the page on 2020, I encourage you to visit HRP on Twitter and join us in looking back at some of the highlights from this challenging year with the hashtag #SRHR stories. Thank you for your collegiality, your expertise and support. It is wonderful to see how, as a global community, we pulled together and did much to support sexual and reproductive health and rights for all.

Read more from the original source:
Message from Director SRH/HRP 28 January 2021 - World Health Organization